Home › Research › Treatments
Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial
Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S.. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2006-08-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective The objective of this study was to compare the efficacy and safety of the moderate-affinity, uncompetitive N-methyl-d-aspartate receptor antagonist, memantine, versus placebo in patients with mild to moderate Alzheimer disease (AD). Method This was a randomized, double-blind, placebo-controlled clinical trial conducted at 42 U.S. sites. Participants were 403 outpatients with mild to moderate AD and Mini-Mental State Examination scores of 10-22 randomized to memantine (20 mg/day; N=201) or placebo (N=202) for 24 weeks. Primary outcomes were change from baseline at 24 weeks on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog), a measure of cognition, and on the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus), a global measure. Secondary outcomes included change on the Neuropsychiatric Inventory (NPI) and the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL(23)), measures of behavior and function, respectively. Results Most (82.4%) participants completed the trial. Memantine resulted in significantly better outcomes than placebo on measures of cognition, global status, and behavior when based on the protocol-specified primary last observation carried forward imputation as well as a mixed-models repeated-measures approach applied to the continuous outcomes. Treatment discontinuations because of adverse events for memantine versus placebo were 19 (9.5%) and 10 (5.0%), respectively. Conclusions These results support the safety and efficacy of memantine for the treatment of mild to moderate AD.
What this study adds
Evidence grade: High
This is a trial of 201 participants. In this 24-week randomized trial of 403 patients with mild to moderate Alzheimer disease, memantine resulted in significantly better outcomes than placebo on measures of cognition, global status, and behavior. Reported effect size: 82.4%; 9.5%; 5.0%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Peskind, E. R., Potkin, S. G., Pomara, N., Ott, B. R., Graham, S. M., Olin, J. T., et al. (2006). Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. https://doi.org/10.1097/01.jgp.0000224350.82719.83
Vancouver
Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2006. doi:10.1097/01.jgp.0000224350.82719.83. PMID: 16861375.
BibTeX
@article{peskind2006-16861375,
author = {Peskind, E. R. and Potkin, S. G. and Pomara, N. and Ott, B. R. and Graham, S. M. and Olin, J. T. and McDonald, S.},
title = {{Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial}},
journal = {The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry},
year = {2006},
doi = {10.1097/01.jgp.0000224350.82719.83},
pmid = {16861375},
url = {https://doi.org/10.1097/01.jgp.0000224350.82719.83}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Objective The objective of this study was to compare the efficacy and safety of the moderate-affinity, uncompetitive N-methyl-d-aspartate receptor antagonist, memantine, versus placebo in patients with mild to moderate Alzheimer disease (AD).
- Results Most (82.4%) participants completed the trial.
- Memantine resulted in significantly better outcomes than placebo on measures of cognition, global status, and behavior when based on the protocol-specified primary last observation carried forward imputation as well as a mixed-models repeated-measures approach applied to the continuous outcomes.
- Treatment discontinuations because of adverse events for memantine versus placebo were 19 (9.5%) and 10 (5.0%), respectively.
- Conclusions These results support the safety and efficacy of memantine for the treatment of mild to moderate AD.
Why it matters
In this 24-week randomized trial of 403 patients with mild to moderate Alzheimer disease, memantine resulted in significantly better outcomes than placebo on measures of cognition, global status, and behavior. Most participants completed the trial.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants201
- Effect size82.4%; 9.5%; 5.0%
- Evidence strengthHigh
How this study scored 73/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. We have no data on senior author's track record, so that was left out: it earned 70 of the 96 points we could judge it on, which is 73 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry) |
| Journal's citation record | 2 / 4 | American Journal of Geriatric Psychiatry: journal h-index 178 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2006 — older than 20 years, still counted |
| Sample size | 2 / 4 | 201 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 6 / 7 | Cited 307 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 14.0 citations a year over 22 year(s) since 2006 |
| Impact for its field and year | 4 / 6 | Cited 17.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 12 other studies in this library |
| Still being cited | 2 / 4 | Cited 23 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 3 / 3 | University of Washington: institution h-index 3,540 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 16861375) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 70 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 70 of the 96 points we could judge it on is 73 out of 100. |
| Total | 73 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
12 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.